Clinical Features and Treatment Outcomes of Langerhans Cell Histiocytosis

Autor: Ho Joon Im, Ki Woong Sung, Hee Young Shin, Kyung Duck Park, Ji Won Lee, Jun Eun Park, Young-Ho Lee, Jin Kyung Suh, Chuhl Joo Lyu, Bin Cho, Jong Jin Seo, Hong Hoe Koo, Byung Kiu Park, Heung Sik Kim, Mee Jeong Lee, Meerim Park, Keon Hee Yoo, Joon Sup Song, Bo Eun Kim, Hack Ki Kim, Nak Gyun Chung, Hee Jo Baek, Kyung Ha Ryu, Hoon Kook, Jae Min Lee, Hoi Soo Yoon, Kwang Chul Lee, Hye Lim Jung, Hyeon Jin Park, Hyoung Jin Kang, Soon Ki Kim, Hwang Min Kim, Soo Hyun Lee, Sang Kyu Park, Yeon Jung Lim, Eun Sil Park, Jeong A Park, Young Tak Lim, Kyung Nam Koh, Eun Sun Yoo, Hyoung Soo Choi, Kun Soo Lee
Rok vydání: 2014
Předmět:
Zdroj: Journal of Pediatric Hematology/Oncology. 36:125-133
ISSN: 1077-4114
Popis: A nationwide survey was conducted to clarify the clinical features and outcomes of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis Working Party analyzed the data of 603 patients who were diagnosed with LCH between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was 65 months (range, 0 to 276 mo). Bone was the most frequently affected organ (79.6%) followed by skin (19.2%). Initially, 419 patients (69.5%) had single-system involvement (SS), 85 (14.1%) with multisystem (MS) disease without risk organ involvement (MS-RO), and 99 (16.4%) multisystem disease with risk organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS, MS-RO, and MS-RO groups were 99.8%, 98.4%, and 77.0%, respectively (P
Databáze: OpenAIRE